Key result
ANGEL-ASPECT trial evaluates endovascular therapy for acute large vessel occlusion with large core infarct.
RCT
Open-label, blinded endpoint
Randomised
Yes
Answers are grounded in this paper and cite their sources.
BACKGROUND: The benefit of stroke thrombectomy for large infarct core still lacks robust randomised controlled studies. AIM: To demonstrate the design of a clinical trial on endovascular therapy for acute anterior circulation large vessel occlusion (LVO) patients with large infarct core volume. DESIGN: ANGEL-ASPECT is a multicentre, prospective, randomised, open-label, blinded End-point trial to evaluate whether best medical management (BMM) combined with endovascular therapy improves neurological functional outcomes as compared with BMM alone in acute LVO patients with Alberta Stroke Program Early CT Score (ASPECTS) of 3-5 on non-contrast CT or infarct core volume range of 70-100 mL (defined as rCBF <30% on CT perfusion or ADC <620 on MRI) up to 24 hours from symptom onset or last seen well. STUDY OUTCOMES: The primary efficacy outcome is 90 (±7) days modified Rankin Scale. Symptomatic intracranial haemorrhage within 48 hours from randomisation is the primary safety outcome. DISCUSSION: The ANGEL-ASPECT trial will screen patients with large infarct core (ASPECTS 3-5 or 70-100 mL) through image evaluation criteria within 24 hours and explore the efficacy and safety of endovascular therapy compared with BMM.
No takes yet. Share an insight, caveat, or question.
Huo et al. (2022) conducted an RCT in Acute anterior circulation large vessel occlusion with large infarct core. Endovascular therapy combined with best medical management vs. Best medical management alone was evaluated on 90 (±7) days modified Rankin Scale. The ANGEL-ASPECT trial protocol is designed to evaluate whether endovascular therapy improves 90-day modified Rankin Scale scores in acute large vessel occlusion patients with a large infarct core.
Synapse has enriched 10 related papers. Consider them for comparative context: